Clinical Trials in Pennsylvania

Showing 4821-4840 of 14,950 trials

reSET-O RCT (Randomized Controlled Trial)

NCT04129580

This randomized controlled trial research study will be evaluating an app, reSET-O, owned by Pear Therapeutics, Inc., to evaluate treatment retention rates in individuals with opioid use disorder after initiating medication assisted treatment.

Opioid-use Disorder

Milton S. Hershey Medical Center100 participantsStarted Sep 2020

Harrisburg, Pennsylvania, United States

TERMINATEDPhase 336 miles

Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

NCT02864953

The primary objective of Part 1 of the study is to determine if BIIB093 improves functional outcome at Day 90 as measured by the modified Rankin Scale (mRS) when compared with placebo in participants with Large Hemispheric Infarction (LHI). The secondary objectives of Part 1 of the study are to determine if BIIB093 improves overall survival at Day 90 when compared with placebo, if BIIB093 improves functional outcome at Day 90 on the mRS dichotomized 0-4 vs. 5-6 when compared with placebo, if BIIB093 reduces midline shift at 72 hours (or at time of decompressive craniectomy \[DC\] or comfort measures only \[CMO\], if earlier) when compared with placebo, and to evaluate the safety and tolerability of BIIB093 in participants with LHI. The objectives of Part 2 of the study are to evaluate long-term disability following LHI, to evaluate long-term outcome measures of clinical function, quality of life, and healthcare utilization, and to assess the safety of BIIB093 in subjects with LHI during the follow-up period.

Brain EdemaStroke, Acute

Remedy Pharmaceuticals, Inc.535 participantsStarted Aug 2018

Phoenix, Arizona, United States • Tucson, Arizona, United States • Palo Alto, California, United States +247 more locations

reSET-O RCT (Randomized Controlled Trial)

Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 (Glibenclamide) for Severe Cerebral Edema Following Large Hemispheric Infarction

Find Trials by Condition in Pennsylvania

Analysis of Both Sex and Device Specific Factors on Outcomes in Patients with Non-Ischemic Cardiomyopathy

A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment

A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot

Glyburide Advantage in Malignant Edema and Stroke Pilot

ME-344 and Bevacizumab in Previously Treated Metastatic Colorectal Cancer

Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.

SELECT2: A Randomized Controlled Trial to Optimize Patient's Selection for Endovascular Treatment in Acute Ischemic Stroke

Pegtibatinase As an Enzyme Therapy for Patients with Homocystinuria Caused by Cystathionine Beta-Synthase Deficiency (COMPOSE)

Aspirin Supplementation for Pregnancy Indicated Risk Reduction In Nulliparas (ASPIRIN)

Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants

Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)

Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder

Observational Study to Assess Migraine Prediction Tool

FPA150 in Patients With Advanced Solid Tumors

Adjunctive Fosfomycin for Treatment of Staphylococcus Aureus Bacteraemia

Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.